Academic Journal
Comparing Glucagon-like peptide-1 receptor agonists versus metformin in drug-naive patients:A nationwide cohort study
| العنوان: | Comparing Glucagon-like peptide-1 receptor agonists versus metformin in drug-naive patients:A nationwide cohort study |
|---|---|
| المؤلفون: | Sørensen, Kathrine Kold, Gerds, Thomas Alexander, Køber, Lars, Loldrup Fosbøl, Emil, Poulsen, Henrik Enghusen, Møller, Amalie Lykkemark, Andersen, Mikkel Porsborg, Pedersen-Bjergaard, Ulrik, Torp-Pedersen, Christian, Zareini, Bochra |
| المصدر: | Sørensen , K K , Gerds , T A , Køber , L , Loldrup Fosbøl , E , Poulsen , H E , Møller , A L , Andersen , M P , Pedersen-Bjergaard , U , Torp-Pedersen , C & Zareini , B 2024 , ' Comparing Glucagon-like peptide-1 receptor agonists versus metformin in drug-naive patients : A nationwide cohort study ' , Journal of Diabetes , vol. 16 , no. 10 , e70000 . https://doi.org/10.1111/1753-0407.70000 |
| سنة النشر: | 2024 |
| المجموعة: | University of Copenhagen: Research / Forskning ved Københavns Universitet |
| الوصف: | Background Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are increasingly being prescribed in drug-naive patients. We aimed to contrast add-on therapy, adherence, and changes in biomarkers, 1 year after treatment initiation with GLP-1 RA or metformin. Methods Using Danish nationwide registers, we included incident GLP-1 RA or metformin users from 2018 to 2021 with glycated hemoglobin (HbA1c) ≥ 42 mmol/mol. GLP-1 RA initiators were matched to metformin initiators in a ratio of 1:1 to assess outcomes in prediabetes and diabetes. Main outcomes analyzed were 1-year risk of add-on glucose-lowering medication and 1-year risk of nonadherence. One-year risks were estimated with multiple logistic regression and standardized. Multiple linear regression was used to estimate the average differences in biomarker changes. Results In total, 1778 individuals initiating GLP-1 RA and metformin were included. After standardizing for various factors, GLP-1 RA compared with metformin was associated with reduced 1-year risk of add-on glucose-lowering treatment in patients with prediabetes (1-year risk ratio [RR]: 0.27, 95% confidence interval [CI]: 0.10–0.44) and diabetes (RR: 0.67, 95% CI: 0.37–0.98). GLP-1 RA was associated with higher 1-year risk of nonadherence among patients with prediabetes (RR: 1.60, 95% CI: 1.45–1.75), but no difference in patients with diabetes (RR: 0.88, 95% CI: 0.70–1.06). Compared to metformin, GLP-1 RA was associated with greater HbA1c reduction (prediabetes: −2.59 mmol/mol 95% CI: −3.10 to −2.09, diabetes: −3.79 mmol/mol, 95% CI: −5.28 to −2.30). Conclusions GLP-1 RA was associated with a reduced risk of additional glucose-lowering medication, achieving better glycated hemoglobin control overall. However, among patients with prediabetes, metformin was associated with better adherence. ; BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are increasingly being prescribed in drug-naive patients. We aimed to contrast add-on therapy, adherence, and changes in biomarkers, 1 year after ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| DOI: | 10.1111/1753-0407.70000 |
| الاتاحة: | https://researchprofiles.ku.dk/da/publications/comparing-glucagonlike-peptide1-receptor-agonists-versus-metformin-in-drugnaive-patients(fb27d7da-f990-4230-b46a-4344293e1c99).html https://doi.org/10.1111/1753-0407.70000 https://curis.ku.dk/ws/files/409206407/Journal_of_Diabetes_2024_S_rensen_Comparing_Glucagon_like_peptide_1_receptor_agonists_versus_metformin_in_drug_naive.pdf |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.21AE2F15 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/1753-0407.70000 |
|---|